ArticleRadiation oncology (London, England)2013
Clinicopathologic features and responses to radiotherapy of myeloid sarcoma.
Article in Radiation oncology (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Ten-Year Outcome of a Patient With Concurrent Pelvic Myeloid Sarcoma and Underlying Chronic Myeloid Leukaemia in Chronic Phase: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.) · 2026Review
- Clinical and Molecular Characterization of Myeloid Sarcoma: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Radiotherapy for Isolated Breast Myeloid Sarcoma.Journal of medical cases · 2025Article
- Article
- Myeloid Sarcoma: Novel Advances Regarding Molecular Pathogenesis, Presentation and Therapeutic Options.Journal of clinical medicine · 2024Review
- Myeloid sarcoma: more and less than a distinct entity.Annals of hematology · 2023Review
- Clinical Characteristics and Treatment Outcomes of Myeloid Sarcoma in Children: The Experience of the Polish Pediatric Leukemia and Lymphoma Study Group.Frontiers in oncology · 2022Article
- Incidence, clinical characteristics, and prognostic nomograms for patients with myeloid sarcoma: A SEER-based study.Frontiers in oncology · 2022Article
- Gastrointestinal Myeloid Sarcoma a Case Presentation and Review of the Literature.Mediterranean journal of hematology and infectious diseases · 2021Review
- Article
- Myeloid Sarcomas Causing Unilateral Cranial Nerve Palsies in a Patient with Relapsed Acute Myeloblastic Leukemia.Case reports in hematology · 2020Article
- Radiotherapy for extramedullary leukaemic manifestation (Chloroma).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Article
- Myeloid Sarcoma of Orbits: Effectiveness of a Low-Dose Radiation Regimen.Case reports in hematology · 2018Article
- Radiotherapy for isolated granulocytic sarcoma: Case report and review of literature.Clinical and translational radiation oncology · 2018Article
- Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.Current treatment options in oncology · 2016Review
- Complete response of myeloid sarcoma with cardiac involvement to radiotherapy.Journal of thoracic disease · 2016Article
- Article
- Long-term loss of osteoclasts and unopposed cortical mineral apposition following limited field irradiation.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015Article
- Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience.International journal of hematology · 2014Article
- Isolated gastric myeloid sarcoma: a case report and review of the literature.Case reports in hematology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate clinicopathological features, radiotherapeutic parameters, and their associations with responses to radiotherapy (RT) in patients with myeloid sarcoma (MS).
methodsWe reviewed 20 patients receiving RT for MS lesions (in 43 RT courses) and analyzed the patients' clinicopathologic features and radiotherapeutic parameters, and their associations with complete responses (CR) to RT using Fisher's exact test and univariate logistic regression analysis. Generalized Estimating Equation was used to analyze all 43 irradiated lesions and account for the correlations in RT responses among lesions from the same patient.
resultsWe found that the underlying hematological diseases of the evaluated patients were acute myeloid leukemia (AML) in 14 patients (70%), chronic myeloid leukemia in 4 patients (20%), myelodysplastic syndrome with AML transformation in one patient (5%), and de novo MS in one patient (5%). Most patients (55%) received RT for MS at the time of relapse following bone marrow transplantation (BMT). The most common cytogenetic abnormality was t(8;21)(q22;q22). The median RT dose of 20 Gy (range 6-35 Gy), administered in 1.5-3.5 Gy fractions, provided a 63% CR rate. RT dose, sex, cytogenetics, and bone marrow status at the time of RT had no significant effect on CR. Younger age (<50 y, P = 0.06), BMT prior to RT (P = 0.05), and underlying AML (P = 0.05) were marginally associated with higher CR to RT.
conclusionsOur results indicate that a modest RT dose (20-30 Gy) achieves good local control of MS. Age, previous BMT, and underlying hematologic disease can affect RT response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.